Lee S, Cho Y, Cha P, Yoon J, Ro E, Jeong W, et al. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med. 2018;50:153 pubmed 出版商

Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A, et al. MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res. 2018;28:719-729 pubmed 出版商

Laviolette L, Mermoud J, Calvo I, Olson N, Boukhali M, Steinlein O, et al. Negative regulation of EGFR signalling by the human folliculin tumour suppressor protein. Nat Commun. 2017;8:15866 pubmed 出版商

Abdi K, Neves G, Pyun J, Kiziltug E, Ahrens A, Kuo C. EGFR Signaling Termination via Numb Trafficking in Ependymal Progenitors Controls Postnatal Neurogenic Niche Differentiation. Cell Rep. 2019;28:2012-2022.e4 pubmed 出版商

Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter J, et al. Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. J Clin Invest. 2018;128:3976-3990 pubmed 出版商

Iskit S, Lieftink C, Halonen P, Shahrabi A, Possik P, Beijersbergen R, et al. Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer. Oncotarget. 2016;7:42859-42872 pubmed 出版商